First Squawk(@FirstSquawk):BAUSCH + LOMB SAYS IT IS ADVANCING TWO FIRST-IN-CLASS EYE HEALTH THERAPIES BASED ON TRIAL RESULTS, WITH ITS DUAL-ACTION EYE DROP SHOWING A SIGNIFICANT REDUCTION IN TCFS AT DAY 15 VERSUS LIFITEGRAST AND ADVANCING INTO PHASE 3, THOUGH THE STUDY FAILED ITS PRIMARY ENDPOINT VERSUS LIFITEGRAST ALONE AT DAY 29, WHILE BL1332 MET ITS PRIMARY ENDPOINT IN PHASE 1B WITH SIGNIFICANT PAIN REDUCTION.

First Squawk

@FirstSquawk

Firstsquawk Is a Global Financial (News) Squawk Service Specialising In Financial Markets, Macro, Geopolitics,politics

Joined July 2015

251 Following 567.8K Followers

First Squawk@FirstSquawk

2026.08.24 20:35

BAUSCH + LOMB SAYS IT IS ADVANCING TWO FIRST-IN-CLASS EYE HEALTH THERAPIES BASED ON TRIAL RESULTS, WITH ITS DUAL-ACTION EYE DROP SHOWING A SIGNIFICANT REDUCTION IN TCFS AT DAY 15 VERSUS LIFITEGRAST AND ADVANCING INTO PHASE 3, THOUGH THE STUDY FAILED ITS PRIMARY ENDPOINT VERSUS LIFITEGRAST ALONE AT DAY 29, WHILE BL1332 MET ITS PRIMARY ENDPOINT IN PHASE 1B WITH SIGNIFICANT PAIN REDUCTION.